Core Viewpoint - Jiahe Meikang (Beijing) Technology Co., Ltd. has faced disciplinary action from the Shanghai Stock Exchange due to accounting errors in its financial reports for 2022 and 2023, leading to significant adjustments in reported profits and net income [2][3] Financial Reporting Issues - The company disclosed multiple announcements on April 30, 2025, correcting accounting errors related to cost recognition and insufficient inventory impairment provisions for 2022 and 2023 [2] - For 2022, total profit was reduced by 4.0544 million yuan, representing a 14.81% decrease, while net profit was adjusted down by 3.4463 million yuan, a decrease of 8.46% [2] - For 2023, total profit was reduced by 11.3478 million yuan, a 169.95% increase in losses, and net profit was adjusted down by 10.213 million yuan, a decrease of 50.35% [2] Disciplinary Actions - The Shanghai Stock Exchange criticized the company and its key executives for failing to ensure accurate financial disclosures, impacting investors' rights [3] - The disciplinary committee found that the company's prior accounting errors were significant and warranted criticism, despite the company's claims of corrective measures [3] Company Performance and Market Position - Jiahe Meikang is a leading provider of medical information technology products and services, holding a 15.0% market share in the electronic medical record system market as of 2024, marking its 11th consecutive year at the top [4] - However, the company has experienced declining revenues, with figures of 717 million yuan in 2022, 695 million yuan in 2023, and a projected 330 million yuan in 2024, reflecting year-on-year changes of -9.97%, -3.04%, -14.85%, and -30.67% respectively [4] - Net profits have also declined significantly, with losses reported at 25.6 million yuan in 2023 and 17.4 million yuan in the first three quarters of 2025 [4] Industry Challenges - The company cited a complex industry environment, with delayed demand from hospital clients, prolonged bidding processes, and increased project implementation costs as factors contributing to revenue decline and losses [5]

根据纪律处分决定，上交所对嘉和美康及时任董事长兼总经理夏军、时任财务负责人任勇予以通报批 评，并将通报中国证监会，记入证券期货市场诚信档案数据库。同时要求公司及董监高采取有效措施整 改，排查合规隐患，提高信息披露和规范运作水平，并在收到决定书后一个月内提交经全体董监高签字 确认的整改报告。 #嘉和美康连续两年报高利润被通报批评#【连续两年"报高"利润，事隔一年才更正，A股公司董事长被 通报批评，并记入诚信档案数据库！此前请求减轻处分被拒】11月28日，嘉和美康公开了一份来自上海 证券交易所（简称上交所）的纪律处分决定书。 记者注意到，针对上述违规事项，嘉和美康公司及有关责任人曾请求减轻处分，但被上交所以所涉时间 跨度长、涉及重要会计科目、调整金额及占比较大等理由拒绝。而且，这家号称"连续11年荣膺我国电 子病历行业市占率第一"的企业，今年上半年的净亏损同比扩大超300%。（每经） 公告显示，公司在今年4月发布了关于前期会计差错更正及定期报告更正的公告，调低了2022年、2023 年的利润总额和净利润，其中2022年的净利润调减344.63万元，占更正前金额的8.46%；2023年的净利 润调减1021.3万元 ...

11月28日，嘉和美康（SH688246，股价24.62元，市值34亿元）公开了一份来自上海证券交易所（简称上交所）的纪律处分决定书。 年报更正事件发生后 财务负责人已换人 公开资料显示，嘉和美康是一家医疗信息化产品及服务提供商，也是国内最早从事医疗信息化软件研发与产业化的企业之一。2021年12月，公司登陆科创 板，次年收入和净利润达到新高度，之后便一路走低。 但今年4月的一纸更正公告，却说明2022年和2023年的年报均有水分。公司2022年度及2023年度成本确认，存在跨期错报、存货跌价准备计提不足，嘉和 美康根据自查结果，对这两年年报中的会计差错进行更正。 具体来说，2022年利润总额调减405.44万元，占更正前金额的14.81%，净利润调减344.63万元，占更正前金额的8.46%；2023年利润总额调减1134.78万 元，占更正前金额的169.95%，净利润调减1021.3万元，占更正前金额的50.35%。 嘉和美康于11月28日发布的公告显示，针对上述违规事项，公司及有关责任人曾提出申辩，称发现错误后积极督促纠正、深刻反省，请求减轻处分。但上 交所纪律处分委员会审核认为，公司会计差错时间跨度 ...

Core Viewpoint - The company Jiahe Meikang has faced significant financial corrections and disciplinary actions from the Shanghai Stock Exchange due to accounting errors that have led to substantial reductions in reported profits for 2022 and 2023 [2][3][4]. Financial Corrections - In April, Jiahe Meikang announced corrections to its financial reports, reducing the net profit for 2022 by 3.4463 million yuan, which is 8.46% of the original amount, and for 2023 by 10.213 million yuan, which is 50.35% of the original amount [2][3]. - The total profit adjustments for 2022 amounted to 4.0544 million yuan (14.81% reduction) and for 2023, 11.3478 million yuan (169.95% increase in losses) [3]. Disciplinary Actions - The Shanghai Stock Exchange issued a disciplinary notice, criticizing the company's former chairman and financial officer, and requiring the company to submit a rectification report within one month [4]. - The company has been instructed to improve its compliance and information disclosure practices [4]. Financial Performance - Jiahe Meikang reported a significant increase in losses, with a net profit of -256 million yuan for 2024, reflecting a year-on-year decline of 893.31% [5]. - The company’s revenue for the first half of the year was 219 million yuan, a decrease of 27.22% year-on-year, with net losses expanding to -116 million yuan, compared to -27.47 million yuan in the same period last year, marking a 323.29% increase in losses [6]. Market Position - Despite being recognized as the leading company in the electronic medical record market in China for eleven consecutive years, Jiahe Meikang's recent financial struggles contrast sharply with its market position [5]. - The company serves over 650 tertiary hospitals, accounting for more than one-third of such hospitals in the country, indicating its significant market presence [5].

证券日报网讯嘉和美康11月25日在互动平台回答投资者提问时表示，截至2025年11月10日，公司的股东 人数为8866户。 （文章来源：证券日报） ...

Core Viewpoint - The AI medical sector experienced a significant increase of 3.48% on November 24, with leading stock performance from Sichuang Medical [1] Group 1: Market Performance - On November 24, the Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] - The top-performing stocks in the AI medical sector included Sichuang Medical, which rose by 8.20% to a closing price of 4.88, and Chengdu Xian Dao, which increased by 6.61% to 22.90 [1] Group 2: Trading Volume and Capital Flow - The AI medical sector saw a net inflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 99.92 million yuan [1] - The trading volume for Sichuang Medical reached 2.345 million shares, with a transaction value of 1.11 billion yuan [1] Group 3: Individual Stock Capital Flow - Notable net inflows from institutional investors included 67.19 million yuan for Weining Health, 38.08 million yuan for Rundar Medical, and 33.69 million yuan for Jiuyuan Yinhai [2] - Conversely, retail investors showed net outflows in several stocks, including 47.88 million yuan for Weining Health and 55.12 million yuan for Jiuyuan Yinhai [2]

Core Viewpoint - The internet healthcare sector experienced a rise of 1.26% on November 24, with Focus Technology leading the gains, while the overall market indices showed modest increases [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3836.77, up 0.05%, and the Shenzhen Component Index closed at 12585.08, up 0.37% [1]. - Focus Technology (002315) saw a significant increase of 9.20%, closing at 48.30, with a trading volume of 224,800 shares and a transaction value of 1.053 billion [1]. - Other notable performers included Sichuang Medical (300078) with an 8.20% increase, closing at 4.88, and Jiahe Meikang (688246) with a 6.45% increase, closing at 24.42 [1]. Group 2: Capital Flow - The internet healthcare sector experienced a net outflow of 89.6577 million from institutional investors, while retail investors saw a net inflow of 763 million [2]. - The leading stocks in terms of net inflow from retail investors included Focus Technology with a net outflow of 97.1479 million, and Jiahe Meikang with a net inflow of 46.0728 million [3]. - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are actively participating [2][3].

Group 1 - The core viewpoint of the news is that Jiahe Meikang has seen a stock price increase of 5.27%, reaching 24.15 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Jiahe Meikang specializes in the research and industrialization of medical information software, with its main business revenue composition being 42.39% from software development and technical services, 37.64% from self-developed software sales, 19.86% from purchased software and hardware sales, and 0.11% from other service sales [1] Group 2 - The fund "Guoxin Guozheng New Profit A" holds 9,000 shares of Jiahe Meikang, unchanged from the previous period, representing 1.26% of the fund's net value, making it the eighth largest holding [2] - The fund has a total scale of 20.6671 million yuan and has achieved a year-to-date return of 11.86%, ranking 4940 out of 8209 in its category [2] - The fund manager, Zhang Honglei, has been in position for 4 years and 80 days, with the best fund return during his tenure being 39.01% and the worst being -13.4% [3]

中国经济网北京11月20日讯 嘉和美康(688246.SH)今日股价下跌，截至收盘报24.08元，跌幅4.52%。 嘉和美康于2021年12月14日在上交所科创板上市，发行价格为39.50元/股，发行数量为3446.94万股，保 荐机构（主承销商）为华泰联合证券有限责任公司，保荐代表人为孔祥熙、王琛。 （责任编辑：马欣） 嘉和美康首次公开发行股票募集资金总额13.62亿元，扣除发行费用后，募集资金净额为12.40亿元。嘉 和美康最终募集资金净额比原计划多4.90亿元。嘉和美康于2021年12月9日披露的招股说明书显示，该 公司拟募集资金7.50亿元，分别用于专科电子病历研发项目（急诊急救方向、妇幼专科方向）、综合电 子病历升级改造项目、数据中心升级改造项目、补充营运资金。 嘉和美康首次公开发行股票的发行费用总额为1.21亿元，其中，保荐及承销费用9782.30万元。 ...

证券日报网讯 11月19日晚间，嘉和美康发布公告称，本次减持计划实施前，公司股东国寿成达（上 海）健康产业股权投资中心（有限合伙）（简称"国寿成达"）持有公司股份12，684，503股，占公司股 份总数的9.22%。公司于近日收到公司股东国寿成达出具的《关于股份减持结果的告知函》，国寿成达 已于2025年10月20日-2025年10月22日期间通过集中竞价方式累计减持所持有的公司股份1，375，855 股，占公司当前股份总数的1%。截至目前，本次减持计划披露的减持时间区间届满。 （文章来源：证券日报） ...